The estimated Net Worth of Marcel Veronneau is at least 2.57 百万$ dollars as of 8 June 2015. Marcel Veronneau owns over 385 units of Bio-Techne Corp stock worth over 2,571,342$ and over the last 22 years Marcel sold TECH stock worth over 0$.
Sign up
Marcel Veronneau TECH stock SEC Form 4 insiders trading
Marcel has made over 5 trades of the Bio-Techne Corp stock since 2011, according to the Form 4 filled with the SEC. Most recently Marcel exercised 385 units of TECH stock worth 30,573$ on 8 June 2015.
The largest trade Marcel's ever made was exercising 567 units of Bio-Techne Corp stock on 1 July 2013 worth over 28,027$. On average, Marcel trades about 87 units every 53 days since 2003. As of 8 June 2015 Marcel still owns at least 34,989 units of Bio-Techne Corp stock.
You can see the complete history of Marcel Veronneau stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Marcel Veronneau's mailing address?
Marcel's mailing address filed with the SEC is , , , , .
Insiders trading at Bio-Techne Corp
Over the last 22 years, insiders at Bio-Techne Corp have traded over 37,160,097$ worth of Bio-Techne Corp stock and bought 4,361 units worth 454,370$ . The most active insiders traders include Charles R. Kummeth、Rupert Vessey、John L Higgins. On average, Bio-Techne Corp executives and independent directors trade stock every 23 days with the average trade being worth of 964,850$. The most recent stock trade was executed by Kim Kelderman on 29 August 2024, trading 1,492 units of TECH stock currently worth 99,919$.
What does Bio-Techne Corp do?
bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.
What does Bio-Techne Corp's logo look like?
Complete history of Marcel Veronneau stock trades at Bio-Techne Corp
Bio-Techne Corp executives and stock owners
Bio-Techne Corp executives and other stock owners filed with the SEC include:
-
Charles Kummeth,
President, Chief Executive Officer, Director -
Charles R. Kummeth,
CEO, Pres & Director -
James Hippel,
Chief Financial Officer, Executive Vice President - Finance -
David Eansor,
President - Protein Sciences -
Kim Kelderman,
President - Diagnostics and Genomics -
Brenda Furlow,
Senior Vice President, General Counsel, Corporate Secretary -
James T. Hippel,
Exec. VP of Fin. & CFO -
Norman David Eansor,
Pres of Protein Sciences Segment -
Kim Kelderman,
Pres of Diagnostics & Genomics -
Brenda S. Furlow J.D.,
Exec. VP, Gen. Counsel, Sec. & Chief Compliance Officer -
Robert Baumgartner,
Independent Chairman of the Board -
Rupert Vessey,
Independent Director -
John Higgins,
Independent Director -
Randolph Steer,
Independent Director -
Roeland Nusse,
Independent Director -
Alpna Seth,
Independent Director -
Joseph Keegan,
Independent Director -
David Clair,
IR Contact Officer -
Julie Bushman,
Independent Director -
Kevin Smyth,
Sr. VP & Chief Digital Officer -
Luca Cicchetti,
Managing Director -
Brenda Everson,
Sr. VP of HR -
Kevin S. Gould,
Sr. VP of Diagnostics Reagents Division -
Struan Robertson,
VP of HR -
Robert M. Gavin,
VP of Corp. Devel. -
Gerry Andros,
VP of Sales and Marketing -
Karen A Holbrook,
Director -
Roger C Lucas,
-
Charles A Dinarello,
-
J. Fernando Bazan,
Chief Technical Officer -
Robert M. Gavin,
Sen. VP Protein Platforms -
Kevin S Gould,
SVP Clinical Controls -
Kevin J Reagan,
Senior VP Biotech -
Gregory J Melsen,
VP Finance and CFO -
Thomas E Oland,
President -
Howard V Oconnell,
Director -
Marcel Veronneau,
Vice Pres-Hematology Oper. -
James A Weatherbee,
Chief Scientific Officers -
Monica Tsang,
Vice President of Research -
Christopher S Henney,
Director -
G A Herbert,
Director -
Harold J Wiens,
-
William Geist,
PRESIDENT, PROTEIN SCIENCES -
Shane Bohnen,
SVP - General Counsel -
Matthew Mc Manus,
President - DGS -
Judith V Klimovsky,
Director